six million), in comparison with Rs 236 crore a year previously. GlaxoSmithKline, which derives almost all of its earnings from India, continued to grapple with problems next the inclusion of its critical items like Ceftum antibiotic and T-Bact ointment while in the country’s Nationwide Listing of Vital Medicines (NLEM) in September 2022, mandati